Advertisement

Molecular Medicine

, Volume 20, Issue 1, pp 38–45 | Cite as

Decline in Serum Cholinesterase Activities Predicts 2-Year Major Adverse Cardiac Events

  • Yaron Arbel
  • Shani Shenhar-Tsarfaty
  • Nir Waiskopf
  • Ariel Finkelstein
  • Amir Halkin
  • Miri Revivo
  • Shlomo Berliner
  • Itzhak Herz
  • Itzhak Shapira
  • Gad Keren
  • Hermona Soreq
  • Shmuel Banai
Research Article

Abstract

Parasympathetic activity influences long-term outcome in patients with cardiovascular disease, but the underlying mechanism(s) linking parasympathetic activity and the occurrence of major adverse cardiovascular events (MACEs) are incompletely understood. The aim of this pilot study was to evaluate the association between serum cholinesterase activities as parasympathetic biomarkers and the risk for the occurrence of MACEs. Cholinergic status was determined by measuring the cumulative capacity of serum acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) to hydrolyze the AChE substrate acetylthiocholine. Cholinergic status was evaluated in randomly selected patients undergoing cardiac catheterization. The patients were divided into two groups of 100 patients in each group, with or without occurrence of MACEs during a follow-up period of 40 months. Cox regression models adjusted for potential clinical, metabolic and inflammatory confounders served to evaluate association with clinical outcome. We found that patients with MACE presented lower cholinergic status and AChE values at catheterization (1,127 ± 422 and 359 ± 153 nmol substrate hydrolyzed per minute per milliliter, respectively) than no-MACE patients (1,760 ± 546 and 508 ± 183 nmol substrate hydrolyzed per minute per milliliter, p < 0.001 and p < 0.001, respectively), whose levels were comparable to those of matched healthy controls (1,622 ± 303 and 504 ± 126 nmol substrate hydrolyzed per minute per milliliter, respectively). In a multivariate analysis, patients with AChE or total cholinergic status values below median showed conspicuously elevated risk for MACE (hazard ratio 1.85 (95% confidence interval (CI) 1.09–3.15, p = 0.02) and 2.21 (95% CI 1.22–4.00, p = 0.009)) compared with those above median, even after adjusting for potential confounders. We conclude that parasympathetic dysfunction expressed as reduced serum AChE and AChE activities in patients compared to healthy controls can together reflect impaired parasympathetic activity. This impairment predicts the risk of MACE up to 40 months in such patients. Monitoring these parasympathetic parameters might help in the risk stratification of patients with cardiovascular disease.

Supplementary material

10020_2014_2001038_MOESM1_ESM.pdf (79 kb)
Supplementary material, approximately 80 KB.

References

  1. 1.
    Jouven X, et al. (2005) Heart-rate profile during exercise as a predictor of sudden death. N. Engl. J. Med. 352:1951–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. (1999) Heart-rate recovery immediately after exercise as a predictor of mortality. N. Engl. J. Med. 341:1351–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Leeper NJ, et al. (2007) Prognostic value of heart rate increase at onset of exercise testing. Circulation. 115:468–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Lahiri MK, Kannankeril PJ, Goldberger JJ. (2008) Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J. Am. Coll. Cardiol. 51:1725–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Adabag AS, et al. (2008) Relation of heart rate parameters during exercise test to sudden death and all-cause mortality in asymptomatic men. Am. J. Cardiol. 101:1437–43.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Arena R, Guazzi M, Myers J, Peberdy MA. (2006) Prognostic value of heart rate recovery in patients with heart failure. Am. Heart J. 151:851.e7–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Savonen KP, et al. (2008) Chronotropic incompetence and mortality in middle-aged men with known or suspected coronary heart disease. Eur. Heart J. 29:1896–902.CrossRefPubMedGoogle Scholar
  8. 8.
    Soreq H, Seidman S. (2001) Acetylcholinesterase: new roles for an old actor. Nat. Rev. Neurosci. 2:294–302.CrossRefPubMedGoogle Scholar
  9. 9.
    Loewenstein-Lichtenstein Y, et al. (1995) Genetic predisposition to adverse consequences of anti-cholinesterases in “atypical” BCHE carriers. Nat. Med. 1:1082–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Goliasch G, et al. (2012) Routinely available bio-markers improve prediction of long-term mortality in stable coronary artery disease: the Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score. Eur. Heart J. 3:2282–9.CrossRefGoogle Scholar
  11. 11.
    Metz CN, Tracey KJ. (2005) It takes nerve to dampen inflammation. Nat. Immunol. 6:756–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Shaked I, et al. (2009) MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity. 31:965–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Borovikova LV, et al. (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 405:458–62.CrossRefGoogle Scholar
  14. 14.
    Ofek K, et al. (2007) Cholinergic status modulations in human volunteers under acute inflammation. J. Mol. Med. (Berlin). 85:1239–1251.CrossRefGoogle Scholar
  15. 15.
    Arbel Y, et al. (2013) Impact of estimated glomerular filtration rate on vascular disease extent and adverse cardiovascular events in patients without chronic kidney disease. Can. J. Cardiol. 29:1374–81, 2013.CrossRefPubMedGoogle Scholar
  16. 16.
    Steinvil A, et al. (2012) The development of anemia of inflammation during acute myocardial infarction. Int. J. Cardiol. 156:160–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Arbel Y, et al. (2012) Prevalence and predictors of slow flow in angiographically normal coronary arteries. Clin. Hemorheol. Microcirc. 52:5–14.PubMedGoogle Scholar
  18. 18.
    Arbel Y, et al. (2012) Neutrophil/lymphocyt ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis. 225:456–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Ben Assayag E, et al. (2010) Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol. Med. 16:278–86.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bryk B, et al. (2005) Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities. J. Neurochem. 92:1216–27.CrossRefPubMedGoogle Scholar
  21. 21.
    Canaani J, et al. (2010) Serum AChE activities predict exercise heart rate parameters of asymptomatic individuals. Neurosci. Med. 1:43–9.CrossRefGoogle Scholar
  22. 22.
    Shenhar-Tsarfaty S, et al. (2011) Butyrylcholinesterase interactions with amylin may protect pancreatic cells in metabolic syndrome. J. Cell. Mol. Med. 15:1747–56.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Shenhar-Tsarfaty S, Ben Assayag E, Bornstein NM, Berliner S, Soreq H. (2011) Post-stroke cholinergic biomarkers [response]. Science [Internet]. [cited 2014 Jan 7]. Available from: https://doi.org/www.sciencemag.org/content/334/6052/101/reply#sci_el_16350.
  24. 24.
    Waiskopf N, Shweky I, Lieberman I, Banin U, Soreq H. (2011) Quantum dot labeling of butyryl-cholinesterase maintains substrate and inhibitor interactions and cell adherence features. ACS Chem. Neurosci. 2:141–50.CrossRefPubMedGoogle Scholar
  25. 25.
    Waiskopf N, Shweky I, Lieberman I, Banin U, Soreq H. (2011) Quantum Dot Labeling of Butyrylcholinesterase Maintains Substrate and Inhibitor Interactions and cell Adherence Features. ACS Chem. Neurosci. 2:141–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Cheung J, et al. (2012) Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J. Med. Chem. 55:10282–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Wandhammer M, et al. (2011) Structural study of the complex stereoselectivity of human butyryl-cholinesterase for the neurotoxic V-agents. J. Biol. Chem. 286:16783–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Berman HM, et al. (2000) The protein data bank. Nucl. Acids Res. 28:235–42.CrossRefPubMedGoogle Scholar
  29. 29.
    Hamm CW, et al. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32:2999–3054.CrossRefPubMedGoogle Scholar
  30. 30.
    Gilson MK, et al. (1994) Open “back door” in a molecular dynamics simulation of acetylcholinesterase. Science. 263:1276–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Calderon-Margalit R, Adler B, Abramson JH, Gofin J, Kark JD. (2006) Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin. Chem. 52:845–52.CrossRefPubMedGoogle Scholar
  32. 32.
    Grisaru D, et al. (2006) Hydrolytic and nonenzymatic functions of acetylcholinesterase comodulate hemopoietic stress responses. J. Immunol. 176:27–35.CrossRefPubMedGoogle Scholar
  33. 33.
    Rosas-Ballina M, et al. (2011) Acetylcholine synthesizing T cells relay neural signals in a vagus nerve circuit. Science. 334:98–101.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Tracey KJ. (2010) Understanding immunity requires more than immunology. Nat. Immunol. 11:561–4.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Meisel C, Meisel A. (2011) Suppressing immunosuppression after stroke. N. Engl. J. Med. 365:2134–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Shenhar-Tsarfaty S, Berliner S, Bornstein NM, Soreq H. (2013) Cholinesterases as biomarkers for parasympathetic dysfunction and inflammation-related disease. J. Mol. Neurosci. 2013, November 20 [Epub ahead of print].Google Scholar
  37. 37.
    Kon H, et al. (2006) Association of decreased variation of R-R interval and elevated serum C-reactive protein level in a general population in Japan. Int. Heart J. 47:867–76.CrossRefPubMedGoogle Scholar
  38. 38.
    Bibevski S, Dunlap ME. (2011) Evidence for impaired vagus nerve activity in heart failure. Heart Fail. Rev. 16:129–35.CrossRefPubMedGoogle Scholar
  39. 39.
    Binkley PF, et al. (1993) Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J. Am. Coll. Cardiol. 21:655–61.CrossRefPubMedGoogle Scholar
  40. 40.
    Du XJ, Cox HS, Dart AM, Esler MD. (1998) Depression of efferent parasympathetic control of heart rate in rats with myocardial infarction: effect of losartan. J. Cardiovasc. Pharmacol. 31:937–44.CrossRefPubMedGoogle Scholar
  41. 41.
    Shaked I, et al. (2009) MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity. 31:965–73.CrossRefPubMedGoogle Scholar
  42. 42.
    Shaltiel G, et al. (2013) Hippocampal microRNA-132 mediates stress-inducible cognitive deficits through its acetylcholinesterase target. Brain Struct. Funct. 218:59–72.CrossRefPubMedGoogle Scholar
  43. 43.
    Maharshak N, et al. MicroRNA-132 modulates cholinergic signaling in inflammatory bowel disease. Inflammatory Bowel Diseases. In press.Google Scholar
  44. 44.
    Lau P, et al. Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol. Med. 5:1613–34.Google Scholar
  45. 45.
    Kaufer D, Friedman A, Seidman S, Soreq H. (1998) Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature. 393:373–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Sailaja BS, Cohen-Carmon D, Zimmerman G, Soreq H, Meshorer E. (2012) Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4. Proc. Natl. Acad. Sci. U. S. A. 109:E3687–95.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Yaron Arbel
    • 1
  • Shani Shenhar-Tsarfaty
    • 2
  • Nir Waiskopf
    • 2
  • Ariel Finkelstein
    • 1
  • Amir Halkin
    • 1
  • Miri Revivo
    • 1
  • Shlomo Berliner
    • 3
  • Itzhak Herz
    • 1
  • Itzhak Shapira
    • 1
  • Gad Keren
    • 1
  • Hermona Soreq
    • 2
    • 4
  • Shmuel Banai
    • 1
  1. 1.Department of Cardiology, Tel Aviv Medical Center, affiliated with the Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  2. 2.Department of Biological Chemistry, The Life Sciences Institute and the Edmond and Lily Safra Center of Brain ScienceThe Hebrew University of JerusalemJerusalemIsrael
  3. 3.Internal Medicine “E,” Tel Aviv Medical Center, affiliated with the Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  4. 4.JerusalemIsrael

Personalised recommendations